{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T07:31:33Z","timestamp":1775979093596,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.phrs.2012.01.004","type":"journal-article","created":{"date-parts":[[2012,1,28]],"date-time":"2012-01-28T07:22:00Z","timestamp":1327735320000},"page":"430-436","source":"Crossref","is-referenced-by-count":47,"title":["Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?"],"prefix":"10.1016","volume":"65","author":[{"given":"Pitchai","family":"Balakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Kadian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanjaian","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2012.01.004_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000324941","article-title":"Obesity, metabolic syndrome and diabetic nephropathy","volume":"170","author":"Maric","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0010","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/ki.2010.513","article-title":"Need for better diabetes treatment for improved renal outcome","volume":"120","author":"Rossing","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.phrs.2012.01.004_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.phrs.2009.02.002","article-title":"Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions","volume":"60","author":"Balakumar","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11010-009-0132-3","article-title":"Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?","volume":"330","author":"Balakumar","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.phrs.2012.01.004_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3810\/pgm.2011.05.2289","article-title":"The role of angiotension receptor blockers in diabetic nephropathy","volume":"123","author":"Sharma","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.phrs.2012.01.004_bib0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrendo.2011.14","article-title":"Do fibrates truly preserve kidney function?","volume":"7","author":"Udani","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2012.01.004_bib0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrneph.2010.59","article-title":"Role of triglyceride-rich lipoproteins in diabetic nephropathy","volume":"6","author":"Rutledge","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3181\/0705-MR-134","article-title":"Diabetic nephropathy: mechanisms of renal disease progression","volume":"233","author":"Kanwar","year":"2008","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.phrs.2012.01.004_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FJC.0b013e3181ad2190","article-title":"Pathogenesis of diabetic nephropathy: involvement of multifaceted signalling mechanism","volume":"54","author":"Balakumar","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-11-0122","article-title":"Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats","volume":"210","author":"Bilan","year":"2011","journal-title":"J Endocrinol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0060","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2012.01.004_bib0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdiacomp.2005.11.001","article-title":"Glucosuria and albuminuria in diabetic nephropathy: a consideration at nanolevel","volume":"21","author":"Wiwanitkit","year":"2007","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.phrs.2012.01.004_bib0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1470320308098343","article-title":"Experimental models for nephropathy","volume":"9","author":"Balakumar","year":"2008","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.phrs.2012.01.004_bib0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2010.03.002","article-title":"The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy","volume":"636","author":"Arora","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2011.06.029","article-title":"Does microvascular disease predict macrovascular events in type 2 diabetes?","volume":"218","author":"Rosenson","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2012.01.004_bib0085","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2337\/diabetes.54.8.2328","article-title":"Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB db\/db mice with type 2 diabetes","volume":"54","author":"Wang","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2012.01.004_bib0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrs.2009.01.010","article-title":"Emerging role of PPAR ligands in the management of diabetic nephropathy","volume":"60","author":"Balakumar","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-008-9917-z","article-title":"Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat","volume":"320","author":"Balakumar","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.phrs.2012.01.004_bib0100","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1194\/jlr.M002972","article-title":"Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice","volume":"51","author":"Taneja","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4093\/dmj.2011.35.3.264","article-title":"Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management","volume":"35","author":"Kang","year":"2011","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.phrs.2012.01.004_bib0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1523-1755.2001.00766.x","article-title":"Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease","volume":"60","author":"Guan","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2012.01.004_bib0115","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.3132\/dvdr.2007.052","article-title":"Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR alpha","volume":"4","author":"Plutzky","year":"2007","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138161209787315701","article-title":"Fibrates and microvascular complications in diabetes--insight from the FIELD study","volume":"15","author":"Ansquer","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.phrs.2012.01.004_bib0125","doi-asserted-by":"crossref","first-page":"828531","DOI":"10.1155\/2010\/828531","article-title":"Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats","volume":"2010","author":"Olukman","year":"2010","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0130","doi-asserted-by":"crossref","first-page":"F667","DOI":"10.1152\/ajprenal.2000.278.4.F667","article-title":"Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure","volume":"278","author":"Portilla","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ki.2009.330","article-title":"Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury","volume":"76","author":"Li","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2012.01.004_bib0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11883-007-0013-8","article-title":"Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials","volume":"9","author":"Farmer","year":"2007","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.phrs.2012.01.004_bib0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbrc.2010.03.043","article-title":"PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity","volume":"394","author":"Hou","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2012.01.004_bib0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000326849","article-title":"Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus","volume":"34","author":"Wanner","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0155","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/sj.ki.5000209","article-title":"PPARalpha agonist fenofibrate improves diabetic nephropathy in db\/db mice","volume":"69","author":"Park","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2012.01.004_bib0160","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.phrs.2012.01.004_bib0165","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2012.01.004_bib0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1476-511X-9-144","article-title":"Treatment of dyslipidemia in patients with type 2 diabetes","volume":"9","author":"Vijayaraghavan","year":"2010","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.phrs.2012.01.004_bib0175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.crd.0000188034.76283.5e","article-title":"Management of dyslipidemia in diabetes","volume":"14","author":"Solano","year":"2006","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.phrs.2012.01.004_bib0180","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.mol.0000226115.97436.c0","article-title":"Diabetic dyslipidemia","volume":"17","author":"Adiels","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0185","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0190","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1046\/j.1462-8902.2003.0310.x","article-title":"Lipoprotein abnormalities and their consequences for patients with type 2 diabetes","volume":"5","author":"Krentz","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2012.01.004_bib0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1586\/erc.11.17","article-title":"Diabetic dyslipidemia or \u2018diabetes lipidus\u2019?","volume":"9","author":"Mua\u010devi\u0107-Katanec","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.phrs.2012.01.004_bib0200","first-page":"601","article-title":"Role of lipases, lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus","volume":"49","author":"de Vries","year":"2003","journal-title":"Clin Lab"},{"key":"10.1016\/j.phrs.2012.01.004_bib0205","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2362.2003.01263.x","article-title":"Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins","volume":"33","author":"Borggreve","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.phrs.2012.01.004_bib0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.physbeh.2007.11.049","article-title":"Lipid accumulation in non-adipose tissue and lipotoxicity","volume":"94","author":"van Herpen","year":"2008","journal-title":"Physiol Behav"},{"key":"10.1016\/j.phrs.2012.01.004_bib0215","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ajpath.2011.05.016","article-title":"Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy","volume":"179","author":"Thompson","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0220","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1523-1755.2004.00451.x","article-title":"Heparan sulfate proteoglycans in glomerular inflammation","volume":"65","author":"Rops","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2012.01.004_bib0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-511X-4-2","article-title":"Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes","volume":"4","author":"Wilsie","year":"2005","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.phrs.2012.01.004_bib0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000186959","article-title":"Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy","volume":"61","author":"Makino","year":"1992","journal-title":"Nephron"},{"key":"10.1016\/j.phrs.2012.01.004_bib0235","doi-asserted-by":"crossref","first-page":"29606","DOI":"10.1074\/jbc.M601552200","article-title":"No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy","volume":"281","author":"van den Born","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2012.01.004_bib0240","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/hr.2009.107","article-title":"Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats","volume":"32","author":"Shin","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0245","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2337\/diabetes.55.04.06.db05-1329","article-title":"Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha","volume":"55","author":"Park","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2012.01.004_bib0250","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/MCB.17.4.2166","article-title":"Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors","volume":"17","author":"DiRenzo","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0255","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/bst0290305","article-title":"Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes","volume":"29","author":"Latruffe","year":"2001","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.phrs.2012.01.004_bib0260","first-page":"0","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"201","author":"Rakhshandehroo","year":"2010","journal-title":"PPAR Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0265","first-page":"S419","article-title":"Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study","volume":"120","author":"Keech","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2012.01.004_bib0270","doi-asserted-by":"crossref","first-page":"345098","DOI":"10.1155\/2010\/345098","article-title":"Role of PPAR\u03b1 and its agonist in renal diseases","volume":"2010","author":"Cheng","year":"2010","journal-title":"PPAR Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0275","first-page":"420","article-title":"Lipids and progressive renal failure","volume":"108","author":"Keane","year":"1996","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.phrs.2012.01.004_bib0280","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1046\/j.1523-1755.2000.07503.x","article-title":"The role of lipids in renal disease: future challenges","volume":"75","author":"Keane","year":"2000","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.phrs.2012.01.004_bib0285","first-page":"147","article-title":"Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis","volume":"22","author":"Guijarro","year":"1996","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.phrs.2012.01.004_bib0290","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.biopha.2008.08.008","article-title":"Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?","volume":"63","author":"Balakumar","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.phrs.2012.01.004_bib0295","first-page":"247","article-title":"Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy","volume":"65","author":"Watanabe","year":"2011","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.phrs.2012.01.004_bib0300","first-page":"3","article-title":"Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes?","volume":"29","author":"Jankun","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.phrs.2012.01.004_bib0305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00011-006-6190-z","article-title":"Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats","volume":"57","author":"Chen","year":"2008","journal-title":"Inflamm Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0310","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.vph.2006.01.004","article-title":"Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1","volume":"44","author":"Chen","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000324949","article-title":"Transforming growth factor-\u03b2 and Smads","volume":"170","author":"Lan","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0320","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1681\/ASN.2010111168","article-title":"Smad3-mediated upregulation of miR-21 promotes renal fibrosis","volume":"22","author":"Zhong","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0325","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1258\/ebm.2009.009218","article-title":"Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-\u03baB and transforming growth factor-\u03b21\/Smad3 in diabetic nephropathy","volume":"235","author":"Li","year":"2010","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.phrs.2012.01.004_bib0330","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfr613","article-title":"High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPAR\u03b1-FoxO3a-PGC-1\u03b1 pathway","author":"Chung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.phrs.2012.01.004_bib0335","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/ki.2010.530","article-title":"Fenofibrate, a PPAR\u03b1 agonist, has renoprotective effects in mice by enhancing renal lipolysis","volume":"79","author":"Tanaka","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2012.01.004_bib0340","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1681\/ASN.2006070798","article-title":"Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice","volume":"17","author":"Zhao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0345","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1681\/ASN.2006050459","article-title":"Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy","volume":"18","author":"Nakagawa","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0350","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1681\/ASN.2006080895","article-title":"Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production","volume":"18","author":"Prabhakar","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0355","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2010.04.020","article-title":"Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation","volume":"60","author":"Tomizawa","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2012.01.004_bib0360","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4103\/0019-5359.48458","article-title":"Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes","volume":"62","author":"Cetinkaya","year":"2008","journal-title":"Indian J Med Sci"},{"key":"10.1016\/j.phrs.2012.01.004_bib0365","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","article-title":"Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report","volume":"65","author":"Wu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phrs.2007.03.002","article-title":"PPAR dual agonists: are they opening Pandora's Box?","volume":"56","author":"Balakumar","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0375","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.3132\/dvdr.2007.053","article-title":"The role of fenofibrate in clinical practice","volume":"4","author":"Zambon","year":"2007","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.phrs.2012.01.004_bib0380","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.phrs.2012.01.004_bib0385","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1046\/j.1365-2362.1997.2330779.x","article-title":"Can reduction in hypertriglyceridemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?","volume":"27","author":"Smulders","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.phrs.2012.01.004_bib0390","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5551\/jat1994.7.91","article-title":"Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients","volume":"7","author":"Nagai","year":"2000","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.phrs.2012.01.004_bib0395","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1476-5381.2011.01597.x","article-title":"Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?","volume":"165","author":"Balakumar","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0400","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2011.09.014","article-title":"Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?","volume":"52","author":"Balakumar","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.phrs.2012.01.004_bib0405","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2146\/ajhp070005","article-title":"Elevated serum creatinine levels associated with fenofibrate therapy","volume":"65","author":"McQuade","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.phrs.2012.01.004_bib0410","first-page":"337","article-title":"Fenofibrate can increase serum creatinine levels in renal insufficiency","volume":"54","author":"Paul","year":"2006","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.phrs.2012.01.004_bib0415","first-page":"41","article-title":"Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency","volume":"20","author":"Hottelart","year":"1999","journal-title":"Nephrologie"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661812000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T20:31:25Z","timestamp":1561235485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661812000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1043661812000059"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2012.01.004","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}